Teleflex Inc. received an upward price target revision from Needham on Monday, reflecting growing confidence in the company’s Freesolve product pipeline.
Needham raised its price target for Teleflex (NYSE: TFX) to $170 from $159, maintaining a Buy rating. The stock last traded at $138.31, implying roughly 23% upside to the new target. Needham also expects Freesolve, a sirolimus-eluting resorbable magnesium scaffold designed for coronary lesions, to contribute an additional 1% to 2% to Teleflex’s annual revenue growth beginning in 2028.
The analyst cited the upcoming BIOMAG-II trial data release, expected in late 2027, as a key catalyst. Positive results from BIOMAG-II could accelerate international sales in 2028, with U.S. commercialization anticipated in 2029. Freesolve is designed to dissolve over a 12-month period following implantation.
Teleflex reported adjusted earnings per share of $1.76 in the second quarter of 2026, exceeding the Wall Street consensus estimate of $1.27. Quarterly revenue totaled $570.3 million, surpassing the forecast of $559.1 million. The company noted lower sales outlook and integration delays in its interventional business as operational headwinds.
Separately, Teleflex executed an accelerated share repurchase agreement with Truist Bank valued at $250 million as part of a broader $1 billion buyback program. The final number of shares repurchased will be determined by the volume-weighted average price during the agreement’s term. According to InvestingPro, 10 analysts have revised their earnings estimates upward for the upcoming period.
